Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394016 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
NCT01394016 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 225 participants.
The verdict
NCT01394016, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.
Interventions
- DRUG Fulvestrant
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2009-12-07 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01394016
The ClinicalTrials.gov registry entry for NCT01394016 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT01394016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01394016 about?
NCT01394016 is a clinical study titled "A Phase 1 Study of LY2835219 In Participants With Advanced Cancer". The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.
What is the current status of trial NCT01394016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2009-12-07. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT01394016?
The interventions under investigation include: Fulvestrant (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT01394016?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.